ファーマコビジランスの世界市場：市場規模・シェア・動向分析 (製品ライフサイクル別・サービスプロバイダー別・種類別・治療領域別・プロセスフロー別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

ファーマコビジランス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のファーマコビジランス（医薬品安全性監視）の市場規模は2030年までに117億8,000万米ドルに達すると予測されています。

2025年から2030年にかけてのCAGRは6.5%で成長が見込まれています。市場成長の主な要因は、副作用（ADR）の発生率の増加です。ADRはヘルスケアシステムに大きな負担をかけ、先進国における罹患率の明らかな根拠の一つとなっています。米国国立生物工学情報センター（NCBI）によると、欧州では年間入院患者数の約20人に1人がADRに起因しています。ファーマコビジランス（PV）サービスは、臨床試験段階において、医薬品に関連する悪影響を認識する上でメーカーを支援することにより、重要な役割を果たしています。

さらに、2022年2月にJournal of Current Medicine Research and Practice誌に掲載された論文「Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs-A Prospective Observational Study（がん化学療法薬を投与される患者における副作用の重大性と結果の特徴-前向き観察研究）」によると、米国では重篤なADRにより年間10万人以上が死亡しており、過去10年来、健康上の大きな懸念となっていることが明らかになりました。致死的不整脈や肝不全などのADRは、医薬品の使用に関連するリスクが関連する利益を上回るため、医薬品の市場からの撤退につながる可能性があります。COVID-19の大流行は、PVサービスプロバイダーにとってチャンスと課題の両方をもたらし、競争力を高めるための革新的なプラットフォームの開発につながりました。

例えば、2020年12月、ライフサイエンス業界の商用サービスプロバイダーであるEVERSANAは、医薬品開発プロセスの自動化を専門とするライフサイエンス・ソフトウェア企業であるArisGlobalと提携しました。この提携は、エンド・ツー・エンドのPV手順をデジタル化し、より安全で効果的なヘルスケアを世界中で実現することを目的としています。クラウドベースのPVや医薬品安全性プラットフォームのように、技術的に先進的でユーザーフレンドリーなソフトウェアシステム市場は、予測期間中の業界の成長をサポートすると予想されます。例えば、Clinevo Technologiesは、症例処理、薬事申請/AS2ゲートウェイ、PVインテーク、アナリティクス、安全性シグナルなど様々な機能を網羅したクラウドベースのソリューション、Clinevo Safetyを提供しています。

このオールインワン・プラットフォームが市場を牽引しています。さらに、組織的な取り組みがブラジルのような新興市場の成長を支えています。例えば、ブラジルでは製薬業界、学術界、臨床現場、保健当局が参加する患者安全とPVの共同プログラムが導入されました。FIPFARMA（Fundacao Instituto de Pesquisas Farmaceuticas）とPharmacy College（Universidade de Sao Paulo）が提供するこのプログラムは、2つのコホート（2020年と2022年）で30時間のオンラインコースを実施しました。このコースでは、ヘルスケアとファーマコビジランスの概要、医薬品安全性と管理、患者安全文化などの重要なトピックを取り上げました。ワークショップでは、ヘルスケア専門家（HCP）が直面する実際の課題を取り上げ、共同での問題解決を促しました。

ビデオ会議は、HCPを効果的に関与させ、教育し、知識の共有を促進し、考え方の転換を促しました。このイニシアティブは参加者にポジティブな影響を与え、ブラジルにおけるPVの実践を強化しました。先進国の主な製薬企業は、コスト削減と運営費削減のためにPVサービスのアウトソーシングに注力しています。このため、発展途上国のCRO（医薬品開発業務受託機関）にとっては、業界シェア拡大のチャンスとなることが期待されます。開発メーカーは、世界的に高まる患者ニーズを満たすため、製品開発手順の見直しを進めています。こうした要因により、PVサービスの需要は予測期間中に拡大すると予測されます。

さらに、PV業界各社は買収、提携、事業拡大、製品発表などの戦略を実施し、提供する製品の幅を広げ、市場での存在感を高めています。例えば、製薬業界に特化したサービスプロバイダーであるErgomed plcは、2022年2月にADAMAS Consulting Group Limitedを買収しました。ADAMASは医薬品製造、臨床試験監査、PVシステムの品質保証サービスを提供する国際的なコンサルタント会社です。今回の買収額は2,560万ポンド（英ポンド）で、エルゴメッド社の収益にプラスに働くことが期待されており、将来的にはさらなる成長と戦略的な優位性が見込まれています。

ファーマコビジランス市場：分析概要

• フェーズIVが2024年の売上高シェア75.90%超で市場を席巻しました。これはADRインシデントの増加と市販後調査によるものです。
• 製薬企業がサービスのアウトソーシングにより業務コストの削減を目指したため、2024年のサービスプロバイダー部門では、契約アウトソーシング部門が最大の市場シェアを占めました。
• 2024年のファーマコビジランス市場では、自発報告部門が最大のシェアを占めました。その用途には、新規、重篤、希少なADRの効率的かつ費用対効果の高い検出が含まれます。
• 2024年の治療領域セグメントでは、慢性がん治療におけるバイオ製薬企業の研究努力に後押しされ、がん領域が27.14%超の最大シェアを占めました。
• 症例データ管理は、予測期間中にプロセスフロー分野で最も速いCAGRで成長すると予測されています。
• バイオテクノロジー企業セグメントは、予測期間中に最も速いCAGRで成長すると予測されています。これは、生物製剤、治療薬、遺伝子治療などの新規製品の研究開発に注力しているためです。
• 北米は、新薬開発への投資、有利な規制、研究ユニットや臨床試験の強力なプレゼンスにより、2024年には32.11%を超える最大の収益シェアを占めました。
• 各社は競争優位を得るため、新製品の上市、提携、買収などの戦略を採用しています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 市場の変動要因・傾向・範囲

• 市場連関の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 業界の機会の分析
  • 業界の課題の分析
• ポーターのファイブフォース分析
  • サプライヤーの力
  • 買い手の力
  • 代替の脅威
  • 新規参入の脅威
  • 競争企業間の敵対関係
• PESTLE分析
• バリューチェーン分析
  • 前臨床
  • 臨床
  • PMA
• サービス提供とその需要に対するライフサイクルのマッピング
• 規制の枠組み
  • 規制機関一覧：国別
• 価格モデル
  • 医薬品安全の予算配分：活動別
  • 開発段階別
  • 治療領域別
  • 価格レベル
• 技術タイムラインの概要
  • 技術の変動と採用
  • 太陽光発電の現在の技術情勢
  • IQVIAのAI主導によるファーマコビジランスの変革
  • テックマヒンドラのAI駆動型ファーマコビジランスソリューション
  • AI支援によるPVワークロードの進化
  • ソーシャルメディア
• COVID-19の影響分析
  • 開発と戦略的成果
• 市場動向：
  • リソースのスケーリング
  • ファーマコビジランスの自動化
• インフレの影響
• ケーススタディ
  • 潜在顧客
  • 注目すべき利用事例
  • ケーススタディ1
  • ケーススタディ2
  • ケーススタディ3
  • ケーススタディ4

第4章 ファーマコビジランス市場：製品別の推定・動向分析

• セグメントダッシュボード：製品別
• 市場シェアの変動分析：製品別（2024年・2030年）
• 市場規模の予測と動向分析：製品別（2018～2030年）
  • 前臨床
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 ファーマコビジランス市場：サービスプロバイダー別の推定・動向分析

• セグメントダッシュボード：サービスプロバイダー別
• 市場シェアの変動分析：サービスプロバイダー別（2024年・2030年）
• 市場規模の予測と動向分析：サービスプロバイダー別（2018～2030年）
• 社内
  • 社内市場（2018年～2030年）
• 契約アウトソーシング
  • 契約アウトソーシング市場（2018年～2030年）

第6章 ファーマコビジランス市場：種類別の推定・動向分析

• セグメントダッシュボード：種類別
• 市場シェアの変動分析：種類別（2024年・2030年）
• 市場規模の予測と動向分析：種類別（2018～2030年）
• 自発的な報告
• ADR報告の強化
• 対象を絞った自発的な報告
• コホートイベントモニタリング（CEM）
• EHRマイニング

第7章 ファーマコビジランス市場：プロセスフロー別の推定・動向分析

• セグメントダッシュボード：プロセスフロー別
• 市場シェアの変動分析：プロセスフロー別（2024年・2030年）
• 市場規模の予測と動向分析：プロセスフロー別（2018～2030年）
• 症例データ管理
• 信号検出
• リスク管理システム

第8章 ファーマコビジランス市場：治療領域別の推定・動向分析

• セグメントダッシュボード：治療領域別
• 市場シェアの変動分析：治療領域別（2024年・2030年）
• 市場規模の予測と動向分析：治療領域別（2018～2030年）
• 腫瘍
  • 腫瘍市場（2018年～2030年）
• 神経学
  • 神経学市場（2018年～2030年）
• 呼吸器系
  • 呼吸器システム市場（2018年～2030年）
• その他
  • その他の市場（2018年～2030年）
• 神経学

第9章 ファーマコビジランス市場：地域別の推定・動向分析

• 市場ダッシュボード：地域別
• 市場の主なポイント：地域別
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • ロシア
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 ファーマコビジランス市場：競合分析

• 市場参入企業の分類
• 上場企業
  • 企業の市況分析
  • 企業の市場シェア分析
• 競合要因と戦略
  • 戦略的コラボレーションと製品発売の増加
  • 協力を含む政府の戦略的取り組み
  • 競合はPV啓発プログラムを強化
  • 競合は業務の連携とアウトソーシングの強化
  • 統合動向

第11章 競合情勢

• 企業プロファイル
  • Accenture
  • IQVIA Inc.
  • Cognizant
  • Clinquest Group BV（Linical Americas）
  • IBM
  • Laboratory Corporation of America Holdings
  • ArisGlobal
  • Capgemini
  • ITClinical
  • ICON plc.
  • TAKE Solutions Limited
  • Parexel International（MA）Corporation
  • Wipro
  • United BioSource LLC
  • BioClinica Inc.（Clario）
  • ClinChoice（formerly FMD K&L）

第12章 勝利戦略

• 主な勝利/採点基準
  • カテゴリー別
  • ベンダー選定の主要要素

第13章 スイッチングコスト分析

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. North America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 4. North America Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 5. North America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 6. North America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 7. North America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 8. North America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 9. North America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 10. U.S. Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 11. U.S. Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 12. U.S. Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 13. U.S. Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 14. U.S. Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 15. U.S. Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 16. Canada Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 17. Canada Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 18. Canada Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 19. Canada Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 20. Canada Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 21. Canada Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 22. Mexico Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 23. Mexico Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 24. Mexico Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 25. Mexico Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 26. Mexico Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 27. Mexico Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 28. Europe Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 29. Europe Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 30. Europe Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 31. Europe Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 32. Europe Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 33. Europe Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 34. UK Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 35. UK Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 36. UK Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 37. UK Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 38. UK Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 39. UK Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 40. Germany Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 41. Germany Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 42. Germany Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 43. Germany Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 44. Germany Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 45. Germany Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 46. France Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 47. France Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 48. France Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 49. France Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 50. France Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 51. France Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 52. Italy Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 53. Italy Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 54. Italy Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 55. Italy Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 56. Italy Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 57. Italy Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 58. Spain Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 59. Spain Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 60. Spain Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 61. Spain Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 62. Spain Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 63. Spain Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 64. Russia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 65. Russia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 66. Russia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 67. Russia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 68. Russia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 69. Russia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 70. Norway Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 71. Norway Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 72. Norway Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 73. Norway Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 74. Norway Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 75. Norway Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 76. Sweden Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 77. Sweden Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 78. Sweden Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 79. Sweden Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 80. Sweden Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 81. Sweden Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 82. Denmark Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 83. Denmark Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 84. Denmark Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 85. Denmark Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 86. Denmark Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 87. Denmark Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 88. Asia Pacific Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 89. Asia Pacific Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 90. Asia Pacific Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 91. Asia Pacific Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 92. Asia Pacific Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 93. Asia Pacific Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 94. Asia Pacific Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
• Table 95. Japan Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 96. Japan Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 97. Japan Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 98. Japan Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 99. Japan Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 100. China Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 101. China Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 102. China Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 103. China Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 104. China Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 105. China Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 106. India Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 107. India Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 108. India Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 109. India Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 110. India Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 111. India Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 112. Australia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 113. Australia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 114. Australia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 115. Australia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 116. Australia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 117. Australia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 118. South Korea Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 119. South Korea Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 120. South Korea Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 121. South Korea Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 122. South Korea Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 123. South Korea Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 124. Thailand Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 125. Thailand Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 126. Thailand Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 127. Thailand Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 128. Thailand Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 129. Thailand Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 130. Latin America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 131. Latin America Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 132. Latin America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 133. Latin America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 134. Latin America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 135. Latin America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 136. Latin America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 137. Brazil Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 138. Brazil Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 139. Brazil Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 140. Brazil Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 141. Brazil Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 142. Brazil Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 143. Argentina Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 144. Argentina Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 145. Argentina Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 146. Argentina Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 147. Argentina Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 148. Argentina Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 149. Middle East & Africa Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
• Table 150. Middle East & Africa Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 151. Middle East & Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 152. Middle East & Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 153. Middle East & Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 154. Middle East & Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 155. Middle East & Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 156. South Africa Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 157. South Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 158. South Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 159. South Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 160. South Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 161. South Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 162. Saudi Arabia Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
• Table 163. Saudi Arabia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 164. Saudi Arabia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 165. Saudi Arabia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 166. Saudi Arabia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 167. Saudi Arabia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 168. UAE Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 169. UAE Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 170. UAE Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 171. UAE Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 172. UAE Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 173. UAE Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
• Table 174. Kuwait Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
• Table 175. Kuwait Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
• Table 176. Kuwait Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
• Table 177. Kuwait Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
• Table 178. Kuwait Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
• Table 179. Kuwait Pharmacovigilance market, end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Pharmacovigilance market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market formulation & validation
• Fig. 6 Market research approaches
• Fig. 7 Value-chain-based sizing & forecasting
• Fig. 8 QFD modelling for market share assessment
• Fig. 9 Commodity flow analysis
• Fig. 10 Market snapshot
• Fig. 11 Market segmentation (USD Million)
• Fig. 12 Competitive landscape
• Fig. 13 Parent market outlook (In USD Billion)
• Fig. 14 Related/ancillary market outlook (In USD Billion)
• Fig. 15 Pharmacovigilance market dynamics
• Fig. 16 Pharmacovigilance market: Porter's five forces analysis
• Fig. 17 Pharmacovigilance market: PESTLE analysis
• Fig. 18 Pharmacovigilance market: product life cycle segment dashboard
• Fig. 19 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
• Fig. 20 Preclinical market, 2018 - 2030 (USD Million)
• Fig. 21 Phase I market, 2018 - 2030 (USD Million)
• Fig. 22 Phase II market, 2018 - 2030 (USD Million)
• Fig. 23 Phase III market, 2018 - 2030 (USD Million)
• Fig. 24 Phase IV market, 2018 - 2030 (USD Million)
• Fig. 25 Pharmacovigilance market: Service provider movement analysis
• Fig. 26 Pharmacovigilance Service provider dashboard
• Fig. 27 Pharmacovigilance market: product life cycle segment dashboard
• Fig. 28 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
• Fig. 29 In-house market, 2018 - 2030 (USD Million)
• Fig. 30 contract outsourcing market, 2018 - 2030 (USD Million)
• Fig. 31 Pharmacovigilance market: Type movement analysis
• Fig. 32 Pharmacovigilance type dashboard
• Fig. 33 Pharmacovigilance market: product life cycle segment dashboard
• Fig. 34 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
• Fig. 35 Spontaneous reporting market, 2018 - 2030 (USD Million)
• Fig. 36 Intensified ADR reporting market, 2018 - 2030 (USD Million)
• Fig. 37 Targeted spontaneous reporting market, 2018 - 2030 (USD Million)
• Fig. 38 CEM market, 2018 - 2030 (USD Million)
• Fig. 39 EHR mining market, 2018 - 2030 (USD Million)
• Fig. 40 Pharmacovigilance market: process flow segment dashboard
• Fig. 41 Pharmacovigilance market: process flow market share analysis, 2024 & 2030
• Fig. 42 Case data management market, 2018 - 2030 (USD Million)
• Fig. 43 Case logging market, 2018 - 2030 (USD Million)
• Fig. 44 Case data analysis market, 2018 - 2030 (USD Million)
• Fig. 45 Medical reviewing and reporting market, 2018 - 2030 (USD Million)
• Fig. 46 Signal detection market, 2018 - 2030 (USD Million)
• Fig. 47 Adverse event logging market, 2018 - 2030 (USD Million)
• Fig. 48 Adverse event analysis market, 2018 - 2030 (USD Million)
• Fig. 49 Adverse event review & reporting market, 2018 - 2030 (USD Million)
• Fig. 50 Risk management system market, 2018 - 2030 (USD Million)
• Fig. 51 Risk Evaluation System market, 2018 - 2030 (USD Million)
• Fig. 52 Risk mitigation system market, 2018 - 2030 (USD Million)
• Fig. 53 Pharmacovigilance market: therapeutic area segment dashboard
• Fig. 54 Pharmacovigilance market: therapeutic area market share analysis, 2024 & 2030
• Fig. 55 Oncology market, 2018 - 2030 (USD Million)
• Fig. 56 Neurology market, 2018 - 2030 (USD Million)
• Fig. 57 Cardiology market, 2018 - 2030 (USD Million)
• Fig. 58 Respiratory systems market, 2018 - 2030 (USD Million)
• Fig. 59 Others market, 2018 - 2030 (USD Million)
• Fig. 60 Pharmacovigilance market: end use segment dashboard
• Fig. 61 Pharmacovigilance market: end use market share analysis, 2024 & 2030
• Fig. 62 Pharmaceuticals market, 2018 - 2030 (USD Million)
• Fig. 63 Biotechnology companies' market, 2018 - 2030 (USD Million)
• Fig. 64 Medical device manufacturers market, 2018 - 2030 (USD Million)
• Fig. 65 Others market, 2018 - 2030 (USD Million)
• Fig. 66 Pharmacovigilance market revenue, by region
• Fig. 67 Regional marketplace: Key takeaways
• Fig. 68 North America Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 US Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 Canada Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Mexico Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Europe Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 UK Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Germany Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 81 Key country dynamics
• Fig. 82 France Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 83 Key country dynamics
• Fig. 84 Italy Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 Spain Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Norway Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 89 Key country dynamics
• Fig. 90 Sweden Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 Denmark Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 93 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 94 Key country dynamics
• Fig. 95 Japan Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 96 Key country dynamics
• Fig. 97 China Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 98 Key country dynamics
• Fig. 99 India Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 100 Key country dynamics
• Fig. 101 Australia Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 102 Key country dynamics
• Fig. 103 South Korea Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 Thailand Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 106 Latin America Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 107 Key country dynamics
• Fig. 108 Brazil Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 109 Key country dynamics
• Fig. 110 Argentina Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 111 Key country dynamics
• Fig. 112 MEA Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 113 Key country dynamics
• Fig. 114 South Africa Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 115 Key country dynamics
• Fig. 116 Saudi Arabia Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 117 Key country dynamics
• Fig. 118 UAE Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 119 Key country dynamics
• Fig. 120 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
• Fig. 121 Key country dynamics
• Fig. 122 Company categorization
• Fig. 123 Company market position analysis
• Fig. 124 Strategic framework

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.5% from 2025 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

• Phase IV dominated the market with a revenue share of over 75.90% in 2024. This was driven by increased ADR incidents and post-marketing surveillance
• contract outsourcing segment held the largest market share in in the service provider segment in 2024, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
• Spontaneous reporting segment dominated the pharmacovigilance market in 2024 with the largest share. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
• Oncology held the largest share of over 27.14% in the therapeutic area segment in 2024, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
• Case data management is anticipated to grow at the fastest CAGR in the process flow segment during the forecast period
• The biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
• North America held the largest revenue share of over 32.11% in 2024 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
• Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Life Cycle
  • 1.2.2. Service Provider
  • 1.2.3. Type
  • 1.2.4. Process Flow
  • 1.2.5. Therapeutic area
  • 1.2.6. End use
  • 1.2.7. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
    • 1.5.4.1. Details of Primary Research
    • 1.5.4.2. Data for primary interviews in North America
    • 1.5.4.3. Data for Primary Interviews in Europe
    • 1.5.4.4. Data for Primary Interviews in APAC
    • 1.5.4.5. Data for Primary Interviews in Latin America
    • 1.5.4.6. Data for Primary Interviews in MEA
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Report Objectives
  • 1.10.1. Objective-1
  • 1.10.2. Objective-2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Segment Snapshot (Product Life Cycle & Type)
  • 2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
  • 2.2.3. Segment Snapshot (End Use)
  • 2.2.4. Competitive Landscape Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing drug consumption and drug development rates
    • 3.2.1.2. Increasing incidence of ADR and drug toxicity
    • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
    • 3.2.1.4. Increasing externalization of clinical trial studies by large
    • 3.2.1.5. Increasing Regulatory Burden on Manufacturers
    • 3.2.1.6. Introduction of technologically advanced software services
      • 3.2.1.6.1. Key focus areas for the pharmaceutical/healthcare companies
      • 3.2.1.6.2. Adoption of technological advancements in Life sciences industry
      • 3.2.1.6.3. Published Survey insights - related to adoption of pharmacovigilance automation
    • 3.2.1.7. Rising investment on R&D by healthcare companies
    • 3.2.1.8. Partnerships and collaborations between market players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shortage of skilled labor
    • 3.2.2.2. Expensive technology for small and mid-sized player
    • 3.2.2.3. Lack of recognition
    • 3.2.2.4. Scarcity of integration standards
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Supplier power
  • 3.3.2. Buyer power
  • 3.3.3. Substitution threat
  • 3.3.4. Threat of new entrant
  • 3.3.5. Competitive rivalry
• 3.4. PESTLE Analysis
• 3.5. Value Chain Analysis
  • 3.5.1. Preclinical
  • 3.5.2. Clinical
  • 3.5.3. PMA
• 3.6. Mapping of Life Cycle Against Service Offering and Their Demand
• 3.7. Regulatory Framework
  • 3.7.1. List of regulatory bodies by Country
• 3.8. Pricing Models
  • 3.8.1. Drug safety budget allocation by activities
  • 3.8.2. By development phase
  • 3.8.3. By therapeutic area
  • 3.8.4. Pricing level
    • 3.8.4.1. Project management
    • 3.8.4.2. Case processing
    • 3.8.4.3. ADR Reporting
    • 3.8.4.4. Medical writing
    • 3.8.4.5. Drug safety management
• 3.9. Technology Timeline Overview
  • 3.9.1. Changing Technology & Adoption
  • 3.9.2. Current Technology Landscape of PV
  • 3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
  • 3.9.4. Tech Mahindra's AI-Driven Pharmacovigilance Solution in
  • 3.9.5. The evolving PV workload with AI assistance
  • 3.9.6. Social Media
    • 3.9.6.1. Literature screening
    • 3.9.6.2. Automation and AI
    • 3.9.6.3. Big data analytics in PV
• 3.10. COVID 19 Impact Analysis
  • 3.10.1. Developments & Strategic Outcomes
    • 3.10.1.1. Regulatory requirements/changes due to covid-19
    • 3.10.1.2. Strategies implemented by companies
      • 3.10.1.2.1. IQVIA
      • 3.10.1.2.2. IBM Corporation
      • 3.10.1.2.3. ArisGlobal
      • 3.10.1.2.4. PAREXEL International Corporation
      • 3.10.1.2.5. Bioclinica
      • 3.10.1.2.6. Pharmaceutical Product Development (PPD)
      • 3.10.1.2.7. ICON, plc
      • 3.10.1.2.8. PRA Health Sciences
      • 3.10.1.2.9. Linical Accelovance
      • 3.10.1.2.10. Laboratory Corporation of America Holdings
• 3.11. Market Trend:
  • 3.11.1. Scaling of resources
  • 3.11.2. Automation in Pharmacovigilance
• 3.12. Impact of Inflation
• 3.13. Case Studies
  • 3.13.1. Potential Customers
  • 3.13.2. Notable Use Cases
  • 3.13.3. Case Study 1
    • 3.13.3.1. Part 1
    • 3.13.3.2. Part 2
  • 3.13.4. Case Study 2
  • 3.13.5. Case Study 3
  • 3.13.6. Case Study 4

Chapter 4. Pharmacovigilance Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Product Market Share Movement Analysis, 2024 & 2030
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.3.1. Preclinical
    • 4.3.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Phase I
    • 4.3.2.1. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Phase II
    • 4.3.3.1. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Phase III
    • 4.3.4.1. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.5. Phase IV
    • 4.3.5.1. Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

• 5.1. Service Provider Dashboard
• 5.2. Service Provider Market Share Movement Analysis, 2024 & 2030
• 5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
• 5.4. In House
  • 5.4.1. In-house market, 2018 - 2030 (USD Million)
• 5.5. Contract Outsourcing
  • 5.5.1. Contract Outsourcing market, 2018 - 2030 (USD Million)

Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis

• 6.1. Type Segment Dashboard
• 6.2. Type Market Share Movement Analysis, 2024 & 2030
• 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Spontaneous Reporting
  • 6.4.1. Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Intensified ADR Reporting
  • 6.5.1. Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Targeted Spontaneous Reporting
  • 6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Cohort Event Monitoring (CEM)
  • 6.7.1. CEM market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. EHR Mining
  • 6.8.1. EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

• 7.1. Process Flow Segment Dashboard
• 7.2. Process Flow Market Share Movement Analysis, 2024 & 2030
• 7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2018 to 2030 (USD Million)
• 7.4. Case data management
  • 7.4.1. Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.1.1. Case logging
      • 7.4.1.1.1. Case logging market, 2018 - 2030 (USD Million)
    • 7.4.1.2. Case data analysis
      • 7.4.1.2.1. Case data analysis market, 2018 - 2030 (USD Million)
    • 7.4.1.3. Medical reviewing and reporting
      • 7.4.1.3.1. Medical reviewing and reporting market, 2018 - 2030 (USD Million)
• 7.5. Signal detection
  • 7.5.1. Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.1.1. Adverse Event Logging
      • 7.5.1.1.1. Adverse event logging market, 2018 - 2030 (USD Million)
    • 7.5.1.2. Adverse Event Analysis
      • 7.5.1.2.1. Adverse Event Analysis market, 2018 - 2030 (USD Million)
    • 7.5.1.3. Adverse Event Review & Reporting
      • 7.5.1.3.1. Adverse Event Review & Reporting market, 2018 - 2030 (USD Million)
• 7.6. Risk Management System
  • 7.6.1. Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.1.1. Risk Evaluation System
      • 7.6.1.1.1. Risk Evaluation market, 2018 - 2030 (USD Million)
    • 7.6.1.2. Risk Mitigation System
      • 7.6.1.2.1. Risk Mitigation market, 2018 - 2030 (USD Million)

Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

• 8.1. Therapeutic Area Segment Dashboard
• 8.2. Therapeutic Area Market Share Movement Analysis, 2024 & 2030
• 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 8.4. Oncology
  • 8.4.1. Oncology market, 2018 - 2030 (USD Million)
• 8.5. Neurology
  • 8.5.1. Neurology market, 2018 - 2030 (USD Million)
• 8.6. Respiratory Systems
  • 8.6.1. Respiratory Systems market, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Other market, 2018 - 2030 (USD Million)
• 8.8. Neurology

Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market: Key Takeaways
• 9.3. North America
  • 9.3.1. North America Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamic
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive insights
    • 9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamic
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive insights
    • 9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2018 - 2030
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamic
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive insights
    • 9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamic
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive insights
    • 9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamic
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive insights
    • 9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamic
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive insights
    • 9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamic
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive insights
    • 9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamic
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive insights
    • 9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Russia
    • 9.4.7.1. Key country dynamic
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive insights
    • 9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamic
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive insights
    • 9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.9. Sweden
    • 9.4.9.1. Key country dynamic
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive insights
    • 9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.10. Norway
    • 9.4.10.1. Key country dynamic
    • 9.4.10.2. Regulatory framework
    • 9.4.10.3. Competitive insights
    • 9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamic
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive insights
    • 9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamic
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive insights
    • 9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamic
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive insights
    • 9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamic
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive insights
    • 9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamic
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive insights
    • 9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamic
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive insights
    • 9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamic
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive insights
    • 9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.2.5. (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamic
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive insights
    • 9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamic
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive insights
    • 9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamic
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive insights
    • 9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamic
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive insights
    • 9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamic
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive insights
    • 9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmacovigilance Market: Competitive Analysis

• 10.1. Market Participant Categorization
• 10.2. Public Companies
  • 10.2.1. Company Market Position Analysis
  • 10.2.2. Company Market Share Analysis
• 10.3. Competitive Factors and Strategies
  • 10.3.1. Increasing Strategic Collaborations and Product Launches
  • 10.3.2. Strategic Government initiatives, including collaborations
  • 10.3.3. Competitors increased PV Awareness programs
  • 10.3.4. Competitors increased collaboration and outsourcing of operations
  • 10.3.5. Consolidation Trends

Chapter 11. Competitive Landscape

• 11.1. Company Profiles
  • 11.1.1. Accenture
    • 11.1.1.1. Overview
    • 11.1.1.2. Financial performance
    • 11.1.1.3. Product benchmarking
    • 11.1.1.4. Strategic initiatives
  • 11.1.2. IQVIA Inc.
    • 11.1.2.1. Overview
    • 11.1.2.2. Financial performance
    • 11.1.2.3. Product benchmarking
    • 11.1.2.4. Strategic initiatives
  • 11.1.3. Cognizant
    • 11.1.3.1. Overview
    • 11.1.3.2. Financial performance
    • 11.1.3.3. Product benchmarking
    • 11.1.3.4. Strategic initiatives
  • 11.1.4. Clinquest Group B.V. (Linical Americas)
    • 11.1.4.1. Overview
    • 11.1.4.2. Financial performance
    • 11.1.4.3. Product benchmarking
    • 11.1.4.4. Strategic initiatives
  • 11.1.5. IBM
    • 11.1.5.1. Overview
    • 11.1.5.2. Financial performance
    • 11.1.5.3. Product benchmarking
    • 11.1.5.4. Strategic initiatives
  • 11.1.6. Laboratory Corporation of America Holdings
    • 11.1.6.1. Overview
    • 11.1.6.2. Financial performance
    • 11.1.6.3. Product benchmarking
    • 11.1.6.4. Strategic initiatives
  • 11.1.7. ArisGlobal
    • 11.1.7.1. Overview
    • 11.1.7.2. Financial performance
    • 11.1.7.3. Product benchmarking
    • 11.1.7.4. Strategic initiatives
  • 11.1.8. Capgemini
    • 11.1.8.1. Overview
    • 11.1.8.2. Financial performance
    • 11.1.8.3. Product benchmarking
    • 11.1.8.4. Strategic initiatives
  • 11.1.9. ITClinical
    • 11.1.9.1. Overview
    • 11.1.9.2. Financial performance
    • 11.1.9.3. Products & Services benchmarking
    • 11.1.9.4. Strategic initiatives
  • 11.1.10. ICON plc.
    • 11.1.10.1. Overview
    • 11.1.10.2. Financial performance
    • 11.1.10.3. Product benchmarking
    • 11.1.10.4. Strategic initiatives
  • 11.1.11. TAKE Solutions Limited
    • 11.1.11.1. Overview
    • 11.1.11.2. Financial performance
    • 11.1.11.3. Product benchmarking
    • 11.1.11.4. Strategic initiatives
  • 11.1.12. Parexel International (MA) Corporation
    • 11.1.12.1. Overview
    • 11.1.12.2. Financial performance
    • 11.1.12.3. Product benchmarking
    • 11.1.12.4. Strategic initiatives
  • 11.1.13. Wipro
    • 11.1.13.1. Overview
    • 11.1.13.2. Financial performance
    • 11.1.13.3. Product benchmarking
    • 11.1.13.4. Strategic initiatives
  • 11.1.14. United BioSource LLC
    • 11.1.14.1. Overview
    • 11.1.14.2. Financial performance
    • 11.1.14.3. Product benchmarking
    • 11.1.14.4. Strategic initiatives
  • 11.1.15. BioClinica Inc. (Clario)
    • 11.1.15.1. Overview
    • 11.1.15.2. Financial performance
    • 11.1.15.3. Product benchmarking
    • 11.1.15.4. Strategic initiatives
  • 11.1.16. ClinChoice (formerly FMD K&L)
    • 11.1.16.1. Overview
    • 11.1.16.2. Financial performance
    • 11.1.16.3. Product benchmarking
    • 11.1.16.4. Strategic initiatives

Chapter 12. Winning Strategies

• 12.1. Key Winning / Scoring Criteria
  • 12.1.1. By Categories
    • 12.1.1.1. Pharmaceuticals
    • 12.1.1.2. Biotech companies
    • 12.1.1.3. Medical device companies
  • 12.1.2. Key Vendor Selection Factors
    • 12.1.2.1. By Category
    • 12.1.2.2. BY Company size
      • 12.1.2.2.1.1. Key Takeaways

Chapter 13. Switching Cost Analysis